STUDY OVERVIEW

LUN24039

Merck V940-009-03 (INTerpath-009)

Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based DoubletChemotherapy



Mechanism of Action

V940: mRNA individualized neoantigen therapy

Patient Population

St II to IIIB (N2) NSCLC

Study Rationale

This randomized study is being conducted to compare the efficacy and safety of neoadjuvant pembrolizumab plus platinum-doublet chemotherapy followed by surgery and adjuvant pembrolizumab with V940 or with placebo in participants with resectable Stage II or IIIA, or IIIB (N2) NSCLC not achieving pCR.

Key Eligibility Criteria

Prior to neoadjuvant therapy:
Able to undergo surgery, receive chemo + pembro (patients

No EGFR or ALK mutations

Squamous and Nonsquamous histologies

Post surgery:
Completed R0-R1

no pCR by local testing

*Patients previously treated outside the study with NA pembro/platinum chemo and completed surgery may advance to screening for randomization

Additional Information

Dr. Susan Johnson (sjohnson@echoct.com)